Wednesday, October 29, 2025 6:30:50 AM
I am well aware of what you are talking about. You people think NWBO should just skip over several important parts of business development when it comes to the stock-market:
1) NWBO does not have a approved drug anywhere in the world.
2 ) NWBO doesn't have a track record of monetizing their technology in any form or fashion. DCVax is a very complex product to produce...from the logistics to the actual making of the vaccine. I 100% think it works based on the science, but I think the larger question Wall Street wants answered is if it can be scaled, monetized and more importantly ADOPTED by the medical community to drive demand. Can it be? I sure hope so. But the jury isnt out until NWBO gets approval somewhere, starts to mass produce DCVax, then gets medical community "buy-in" to increase demand. These are the Qs that need to be answered, until we have some insight on all this via regular, scheduled quarterly calls that are NOT SHROUDED IN SECRECEY , the SP will continue to lag.
1) NWBO does not have a approved drug anywhere in the world.
2 ) NWBO doesn't have a track record of monetizing their technology in any form or fashion. DCVax is a very complex product to produce...from the logistics to the actual making of the vaccine. I 100% think it works based on the science, but I think the larger question Wall Street wants answered is if it can be scaled, monetized and more importantly ADOPTED by the medical community to drive demand. Can it be? I sure hope so. But the jury isnt out until NWBO gets approval somewhere, starts to mass produce DCVax, then gets medical community "buy-in" to increase demand. These are the Qs that need to be answered, until we have some insight on all this via regular, scheduled quarterly calls that are NOT SHROUDED IN SECRECEY , the SP will continue to lag.
Recent NWBO News
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
